Cowan Elvia, the Senior Vice President of Finance and Chief Accounting Officer at Vaxcyte, Inc., has reported several stock transactions in a recent SEC filing. The transactions, which took place on November 2, 2026, are significant as they reflect ongoing changes in ownership stakes within the biological products industry.

In the filing, Elvia reported acquiring 3,000 shares of Vaxcyte's common stock at a price of $25.92 per share through a stock option exercise. Additionally, Elvia sold 2,414 shares at a weighted average price of $60.765 and another 586 shares at a weighted average price of $61.547. Following these transactions, Elvia holds a total of 71,068 shares of Vaxcyte's common stock.

Background

Vaxcyte, Inc. is a company that specializes in the development of biological products, specifically in the area of vaccines. It is classified under the SIC code for Biological Products (No Diagnostic Substances) [2836]. The company is incorporated in Delaware and has its business headquarters in San Carlos, California. Vaxcyte's trading symbol is PCVX.

What the Filing Says

The SEC filing, accession number 0001960048-26-000015, details multiple transactions by Elvia, including both acquisitions and disposals of common stock. The filing states, "The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2025." This indicates that the transactions were part of a pre-arranged plan to manage stock sales and purchases.

Impact

These transactions may affect Vaxcyte's stock performance and investor sentiment. As a senior officer, Elvia's trading activity can be seen as a reflection of the company's health and future prospects. The biological products industry remains competitive, and movements by key executives can influence market perceptions.

What's Next

The filing does not say what happens next.